Phase II Study of ASP3550 [degarelix] - A Maintenance-dose Finding Study in Patients With Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 31 Aug 2018 Biomarkers information updated
- 19 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History